Background: Prostate-specific antigen density (PSAD) is one of the means of improving PSA sensitivity as a marker of a prostate cancer diagnosis. However, this ability is perceived to be obscured by certain factors such as high body mass index and age in Caucasian and western populations, which tends to reduce its sensitivity and lead to misclassification of at-risk patients for prostate cancer. Aim: We studied the correlation of body mass index (BMI) and age with prostate-specific antigen density (PSAD) as indicators of prostate cancer risk in a screened male population(40 years and above) in the University of Calabar, Nigeria. Eyam et al.; JCTI, 9(3): 1-7, 2019; Article no.JCTI.50245 2 Study Design: A cross-sectional analytical study with consecutive participant recruitment. Place and Duration of Study: The study was carried out in the University of Calabar Medical centre during a medical outreach.
INTRODUCTION
Prostate cancer is top on the list among causes of cancer-related deaths in men and ranks as the second most common cancer after lung cancer the world over [1] . In Nigeria, there is a gradual trend of rising prostate cancer cases which is attributable to increasing urbanization and changing dietary habit as well as the increased awareness towards the use of health facilities leading to more cases being documented. Body mass index (BMI) has been linked with aggressive prostate cancer by some studies but its association still requires to be properly established as previous studies have disputed a clear pattern of relationship [2] . Some studies suggest that the effect of BMI on serum prostatespecific antigen levels is inversely related meaning that in obesity or high BMI there is decreased concentration of PSA [1, 2] . It is on this premise therefore that some investigators think that obesity, as evidenced by high BMI, might reduce the sensitivity of screening for prostate cancer with prostate-specific antigen (PSA) [3] . This apparent decrease in sensitivity or of PSA concentration was attributed to the dilution effect resulting from raised plasma volume in obese individuals [3] . High BMI as a strong indicator of obesity, is said to be responsible for the myriad of co-morbidities and is on the rise in transitioning economies like Nigeria [1] . Age and ageing have been associated with changes in prostate-specific antigen level, prostate volume and prostatespecific antigen density (PSAD) with elevations seen with increasing age [4, 5] . PSAD is how PSA secretion per unit volume of prostatic tissue is assessed [6] . Prostate-specific antigen density has also been used to improve the sensitivity of PSA at indeterminate concentrations to detect prostate cancer in men with negative digital rectal examination [7] . High BMI (obesity) has been associated with low prostate-specific antigen density and has a high risk of prostate cancer due to the reduction in sensitivity of the test [2, 8] . Studies have also shown an association between PSAD status and aggressiveness of prostate cancer disease and its usefulness in selecting patients for biopsy and surveillance purposes [9, 10] . In men with high BMI (obesity) the PSAD is seen to be low and therefore are predisposed to the risk of developing prostate cancer disease without being detected early. PSAD and BMI are racedependent and therefore vary along racial lines, [11] and since age also influences the levels of PSA, it is imperative to study these parameters in different ethnic communities, globally [6, 12] .This study, therefore, was conducted to determine the correlation of these prostate cancers influencing indices among apparently healthy men in the University of Calabar, Nigeria.
MATERIALS AND METHODS
This was a cross-sectional analytical study involving sixty-one (61) healthy participants recruited consecutively in a medical outreach carried out in the University of Calabar Medical Center for members of the University community. The participants had already been prepared through instructions on fliers and other media outlets to abstain from sexual intercourse and ejaculation for at least 3 days before the exercise. Informed consent was collected from participants who were 40 years and above and had no previous history of prostate cancer or benign prostatic hyperplasia. The height and weight of all the participants were measured with a stadiometer device and 1 mL of blood samples collected for prostate-specific antigen (PSA) assay before the digital rectal examination (DRE) and transrectal ultrasonography (TRUS) were performed. Two drops of whole blood collected from all 200 participants in attendance were tested by adding unto the test chamber of dry chemistry (Rapid Diaspot) one-step device for PSA assay along with a drop of diluent and was read after 5 minutes. However, only the samples of 61 participants who met the inclusion criteria (abstinence from coitus or masturbation in past three days, not on the urethral catheter, did not have DRE before the presentation) were used as data for statistical analysis following the findings on DRE and TRUS procedures. Body mass index (BMI) was mathematically determined by dividing the weight in Kilograms (Kg) by the square of the height in square meters (m 2 ). The PSAD was also mathematically determined by dividing the PSA by the prostate volume which was estimated with the means of the TRUS.
RESULTS
The socio-demographic findings are presented in Table 1 . The ages of participants were grouped into 40-49 years, 50-59 years and 60 years and above with a range of 40-66 years and mean age of 52.03±7.5 years. The 40-49 years age grouping had a frequency of 22 representing 36.1% of the participating population while the age grouping of 50-59 years had a frequency of 27 which represented 44.3% of the participants and a frequency of 12 was noted for those 60 years and above which represented 19.7% of the sampled population.
The values of PSA concentration were presented in Fig. 1 . Forty one (41) participants representing 67.2% of the sampled population had PSA concentration less than 4.0 ng/mL (< 4.0 ng/mL), while nine (9) of the participants representing 4.8% had PSA values of 4.0-10.0 ng/mL and 11 of the participants had values greater than 10.0 ng/mL (>10.0 ng/mL) representing 18.0% of the sampled population.
The association of age with prostate-specific antigen levels was captured in Table 2 and showed that out of the 22 participants that were within the 40-49 years age grouping 18 of them representing 81.8% had PSA values of less than 4.0 ng/mL and only 2 participants had 4.0-10.0 ng/mL and another 2 greater than 10.0 ng/mL representing 9.1% of each group. The body mass index (BMI) class of participants has illustrated in the pie chart in Fig. 2 . 14.8% of the participants were obese while 50.8% were overweight. The remaining 32.8% and 1.6% were normal weight and underweight respectively.
The body mass index (BMI) and prostate-specific antigen (PSAD) were shown in . The median prostate-specific density (PSAD) was 0.01 ng/mL/cm 3 with the minimum of 0.00 ng/mL/cm 3 and maximum value of 1.00 ng/mL/cm 3 
.
There was an inverse monotonic Spearman correlation of BMI with PSAD as shown in Fig. 3 . PSAD decreased with increased BMI, P = 0.898. 
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Fig. 1. Bar chart showing PSA values of participants
Fig. 2. BMI class of participants
The relationship of age with PSAD has illustrated in Fig. 4 in a scatter plot that showed a moderate direct monotonic spearman's correlation. There was an increase in PSAD with increasing age. P = 0.017.
DISCUSSION
The benefits of early diagnosis of prostate cancer include early commencement of treatment, deferred complications and promotion of good quality of life. Some of the indices that reduce the sensitivity of PSA as a marker of early detection of prostate cancer are body mass index (BMI) and age among Caucasians and western populations. Their correlation with prostatespecific antigen density (PSAD) was assessed in Nigerian men in this study. Our study which was in a healthy population revealed our study group to have predominantly high BMI with over 65% being either in the overweight or obese category. Bonn and colleagues [2] studied the association between high BMI, serum PSA as well as a prostate cancer risk in 15,827 men, and during follow up 735 men were diagnosed with prostate cancer with 38.4% being high-grade cancers. Even though the association was not statistically significant, they concluded BMI was important in risk stratification for prostate cancer. PSAD is known to improve the sensitivity of PSA as a marker of prostate cancer and by extension, factors that affect PSA would affect PSAD. Body mass index (BMI) had an inverse correlation with PSAD (PSAD was observed to decrease with increased BMI). This observation conforms with a previous study in Northwestern Chinese population [1] . The decrease in PSAD masks the detection of patients at risk of prostate cancer due to misclassification. Available literature shows that testosterone is known to improve the normal differentiation of prostatic epithelial tissue and when reduced could lead to poor differentiation that may promote carcinogenesis [13] . High BMI (obesity) is associated with a reduction in testosterone level which suggests that patients with high BMI and low PSAD as was established in this study are prone to the risk of poorly differentiated prostatic epithelial tissue and aggressive prostate cancer. The PSAD was seen to have a direct monotonic correlation with age, by subtly increasing with an increase in age. This was in keeping with published literature in India that showed a similar pattern in PSAD in which there was an increase in PSAD with increasing age and which was attributed to a corresponding increase in prostate volume with age [11] . PSAD is a function of PSA and prostate volume which are seen to increase with the increase in age and therefore is affected by ageing.
CONCLUSION
There was an inverse correlation of BMI with PSAD and a direct correlation of age with PSAD in this study of Nigerian men. Therefore, high BMI and increasing age affect PSAD by reducing its value consequently leading to misclassification of the at-risk patient for prostate cancer disease.
RECOMMENDATION
The use of prostate-specific antigen density (PSAD) as an adjunct tool in the diagnosis of prostate cancer should be used with caution and in conjunction with other parameters, especially in the obese and the elderly.
Further studies on this subject are required with a larger sample size to affirm these findings.
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